Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingSimple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasmaImaging MS in Toxicology: An Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administration.Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.Carbon-carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes.Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.Dabrafenib for the treatment of melanoma.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approachesEvaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.
P2860
Q23923997-E78A1DF2-9958-4712-8AD9-6BC0F9B017B2Q33665825-E1D6A165-0F29-4FBE-9734-DD8129FB820CQ35578108-CDC355AF-B4B7-4C68-83C2-5FB31154C342Q38282958-A5C22B03-3EF5-4907-B6C7-861972D9F524Q38590451-E58844C4-0696-4F15-9600-ED1E432EDAF6Q38836158-066D5876-8678-45AD-820D-B37038D795DDQ38849629-C00CBEF6-4882-4176-898C-C77F29326DC3Q39174413-20673995-C972-4C22-866A-B4BEF7BB643CQ39212238-E128E7EE-88E6-4C46-9F15-560FEC16B65FQ39429946-567F444D-2BC5-4E06-A296-686E2582BED3Q41880361-3F599020-5FA7-412A-B02B-06BD8230C327Q47562754-70777083-8D91-418E-9275-74C94962CAE6Q53080545-29724D1C-74FD-4C3E-99FA-076F223A4219Q54385405-00DDD9F9-46D7-4114-8827-D8C0523969C9
P2860
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Metabolism and disposition of ...... following enzymatic oxidation.
@en
Metabolism and disposition of ...... following enzymatic oxidation.
@nl
type
label
Metabolism and disposition of ...... following enzymatic oxidation.
@en
Metabolism and disposition of ...... following enzymatic oxidation.
@nl
prefLabel
Metabolism and disposition of ...... following enzymatic oxidation.
@en
Metabolism and disposition of ...... following enzymatic oxidation.
@nl
P2093
P356
P1476
Metabolism and disposition of ...... following enzymatic oxidation.
@en
P2093
Dana M Knecht
Daniele Ouellet
David A Bershas
Donna B Mamaril-Fishman
Jerry L Adams
Kristen E Jurusik
Lauren E Richards-Peterson
Noelia Nebot
Royce A Morrison
Samuel C Blackman
P304
P356
10.1124/DMD.113.053785
P577
2013-10-04T00:00:00Z